Catalysts / MRK
Upcoming FDA decisions and readouts we track for Merck & Co., each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Merck & Co. (MRK, listed on NYSE). It concerns Ifinatamab deruxtecan (I-DXd) (Small cell lung cancer).
First on the list: the PDUFA date for Ifinatamab deruxtecan (I-DXd) (Small cell lung cancer), listed for 10 Oct 2026 by a secondary source, not yet confirmed against the company's own filing.
The row links to a third-party catalyst calendar. It still needs confirming against the company's own filing. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Merck & Co. MRK · NYSE | Ifinatamab deruxtecan (I-DXd) | Small cell lung cancer | 10 Oct 2026 in 3d |
PDUFA date | Reported | Catalyst calendar ↗ | Yes |
FreeBioList